NCL

(redirected from Neuronal ceroid lipofuscinosis)
Also found in: Dictionary, Medical, Acronyms, Wikipedia.

NCL

GOST 7.67 Latin three-letter geocode for New Caledonia. The code is used for transactions to and from New Caledonian bank accounts and for international shipping to New Caledonia. As with all GOST 7.67 codes, it is used primarily in Cyrillic alphabets.
References in periodicals archive ?
Polaryx is developing patient-friendly oral small molecule therapeutics for Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) and other forms of NCL, commonly known as Batten disease.
The abnormalities within the central nervous tissues were consistent with a diagnosis of neuronal ceroid lipofuscinosis (NCL).
PPT1 and TPP1 activities in dried blood samples from patients with different forms of neuronal ceroid lipofuscinosis and from healthy controls.
According to BioMarin, BMN 190 is a recombinant human tripeptidyl peptidase 1 (rhTPP1) for the treatment of patients with neuronal ceroid lipofuscinosis type 2 (NCL-2), a form of Batten disease.
Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis.
The request concerns Bio Marin's BMN-190, an investigational recombinant human tripeptidyl peptidase 1 for the treatment of Batten disease, or neuronal ceroid lipofuscinosis type 2 (NCL-2).
The proposed Phase I trial is designed to investigate the safety of HuCNS-SC in the treatment of infantile and late-infantile neuronal ceroid lipofuscinosis (NCL), the most severe forms of a group of disorders commonly referred to as Batten disease.
NASDAQ: STEM) today provided an update on the ongoing clinical development program of its proprietary HuCNS-SC([R]) product candidate (purified human neural stem cells) for neuronal ceroid lipofuscinosis (NCL), often referred to as Batten disease.
s (NASDAQ: BMRN) Brineura (cerliponase alfa), the first treatment approved in the European Union for the treatment of neuronal ceroid lipofuscinosis type 2, also known as tripeptidyl peptidase 1 deficiency, the company said.
5) a-Mannosidosis 5 4 (3-5) MLD (e) 32 5 (0-11) MPS I 18 4 (0-29) MPS II 24 3 (0-11) MPS IIIA 19 5 (1-17) MPS IIIB 16 6 (2-21) MPS IIIC 3 12 (6-20) MPS HID 3 2 (0-3) MPS IVA 16 7 (1-44) MPS VI 10 5 (0-16) Multiple sulphatase deficiency 2 7 (7) Neuronal ceroid lipofuscinosis 1 4 (infantile) (e) Niemann-Pick disease (A/B) (e) 9 26 (2-44) Niemann-Pick disease (C) (e) 10 13 (0-40) Pompe disease (e) 5 0.
Full browser ?